115563
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
放射性125I粒子联合PD-1抑制剂为晚期非小细胞肺癌老年患者提供持续临床获益：一例病例报告
Authors Ouyang SR , Bao XZ, Li YP, He JD
Received 23 September 2025
Accepted for publication 25 December 2025
Published 8 January 2026 Volume 2026:18 569802
DOI https://doi.org/10.2147/CMAR.S569802
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Alessandro Rizzo
Su-Rui Ouyang,1,* Xuan-Zhen Bao,2,* Yi-Ping Li,1 Jing-Dong He1
1Department of Oncology, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huai’an, People’s Republic of China; 2Department of Neurology, Donghai County People’s Hospital, Lianyungang, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Jing-Dong He, Department of Oncology, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huai’an, People’s Republic of China, Tel +86-17551853828, Email 17551853828@163.com
[摘要]放射性125I粒子植入作为一种微创、精准的局部治疗手段，尤其适用于无法耐受传统治疗的老年患者。与此同时，PD-1抑制剂作为研究的一大热点，目前已成为非小细胞肺癌系统治疗的重要组成部分。本病例报告描述了一名72岁晚期非小细胞肺癌男性患者，尽管接受了多线化疗和放疗，疾病仍出现进展。由于出现咯血症状，他接受了放射性125I粒子联合PD-1抑制剂治疗。术后，他的咯血症状完全缓解，并意外发现该患者的无进展生存期达到了40个月，展现出持续的临床获益。该结果提示125I粒子植入与PD-1抑制剂联合治疗可能具有协同抗肿瘤效应，为老年晚期非小细胞肺癌患者的治疗策略提供了新的方向。
1Department of Oncology, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huai’an, People’s Republic of China; 2Department of Neurology, Donghai County People’s Hospital, Lianyungang, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Jing-Dong He, Department of Oncology, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huai’an, People’s Republic of China, Tel +86-17551853828, Email 17551853828@163.com
[摘要]放射性125I粒子植入作为一种微创、精准的局部治疗手段，尤其适用于无法耐受传统治疗的老年患者。与此同时，PD-1抑制剂作为研究的一大热点，目前已成为非小细胞肺癌系统治疗的重要组成部分。本病例报告描述了一名72岁晚期非小细胞肺癌男性患者，尽管接受了多线化疗和放疗，疾病仍出现进展。由于出现咯血症状，他接受了放射性125I粒子联合PD-1抑制剂治疗。术后，他的咯血症状完全缓解，并意外发现该患者的无进展生存期达到了40个月，展现出持续的临床获益。该结果提示125I粒子植入与PD-1抑制剂联合治疗可能具有协同抗肿瘤效应，为老年晚期非小细胞肺癌患者的治疗策略提供了新的方向。